Table 1.
VAP and non VAP MRSA strains.
| Organism(s) | Strain | Islolated from | CFU/ml | VAP (+ / −) | Antibiotic MIC (μg/ml) | |
|---|---|---|---|---|---|---|
| Linezolid | Vancomycin | |||||
|
H. influenzae S. aureus (MRSA) |
VAP 025 | BAL |
104 103 |
+ | 4 (S) | 1 (S) |
| S. aureus (MRSA) | VAP 026 | BAL | 102 | − | 4 (S) | 0.5 (S) |
| S. aureus (MRSA) | VAP 032 | ETA | 106 | − | 4 (S) | 1 (S) |
|
H. influenzae S. aureus (MRSA) |
VAP 034 | BAL + ETA |
104 104 |
+ | 4 (S) | 1 (S) |
| S. aureus (MRSA) | VAP 039 | BAL | 104 | + | 4 (S) | 1 (S) |
|
Aspergillus spp. S.aureus (MRSA) |
VAP 040 | BAL |
102 103 |
− | 4 (S) | 1 (S) |
Six MRSA strains were used and clinically defined as VAP or non VAP from a previous study12. Column 1 shows isolates detected in the original study with MRSA isolated and sub-cultured to produce the work in this manuscript. The strain used throughout this study, VAP39, is highlighted in bold.